tiprankstipranks
Trending News
More News >
Canopy Growth (CGC)
:CGC
US Market
Advertisement

Canopy Growth (CGC) Earnings Dates, Call Summary & Reports

Compare
11,172 Followers

Earnings Data

Report Date
Feb 06, 2026
Before Open (Confirmed)
Period Ending
2026 (Q3)
Consensus EPS Forecast
-0.06
Last Year’s EPS
-0.79
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:Nov 07, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call presented a mixed view: strong growth in Canadian markets and effective cost savings were offset by significant challenges in international markets and potential regulatory risks in Canada.
Company Guidance
During Canopy Growth's Second Quarter Fiscal 2026 Financial Results Conference Call, the company reported a robust performance in its Canadian cannabis business, with net revenue in the adult-use segment increasing by 30% year-over-year, and the medical cannabis segment growing by 17%. The company achieved a significant milestone by narrowing its adjusted EBITDA loss to $3 million, compared to a $6 million loss the previous year. This improvement was driven by rigorous cost-saving initiatives, surpassing a $20 million target with $21 million in annualized savings, and a stronger financial position with $298 million in cash and cash equivalents, exceeding debt balances by $70 million. Canopy Growth also highlighted its plans to enhance its cultivation standards and expand its product lineup, including the launch of the new VEAZY Vaporizer by Storz & Bickel, which contributed to sequential revenue growth. However, the company acknowledged challenges in international markets, specifically in Europe, where net revenues declined by $3 million due to supply constraints, but expressed commitment to improving supply chain execution to stabilize operations by fiscal year's end.
Strong Canadian Adult-Use Cannabis Growth
Net revenue in the Canadian adult-use cannabis business increased by 30% year-over-year in Q2, driven by demand for Claybourne infused pre-rolls and Tweed and 7ACRES All-In-One vapes.
Canadian Medical Cannabis Revenue Increase
Net revenue in the Canadian medical cannabis business grew by 17% year-over-year, marking another consecutive quarter of growth and supported by a 20% increase in patient registrations.
SG&A Savings Surpass Target
The SG&A savings program delivered over $21 million in annualized savings, surpassing the original $20 million target ahead of schedule.
Positive Cash Position and Reduced Debt
Canopy Growth reported $298 million in cash and cash equivalents, exceeding debt balances by $70 million, and prepaid USD 50 million on its senior secured term loan, capturing USD 6.5 million in annualized interest savings.

Canopy Growth (CGC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CGC Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 06, 2026
2026 (Q3)
-0.06 / -
-0.79
Nov 07, 2025
2026 (Q2)
-0.11 / >-0.01
-1.05399.32% (+1.05)
Aug 08, 2025
2026 (Q1)
-0.16 / -0.16
-1.13986.25% (+0.98)
May 30, 2025
2025 (Q4)
-0.33 / -1.02
-0.733-38.83% (-0.28)
Feb 07, 2025
2025 (Q3)
-0.34 / -0.79
-1.86557.63% (+1.07)
Nov 08, 2024
2025 (Q2)
-0.33 / -1.05
-3.06165.58% (+2.01)
Aug 09, 2024
2025 (Q1)
-0.32 / -1.14
-0.498-128.57% (-0.64)
May 30, 2024
2024 (Q4)
-0.32 / -0.73
-9.11191.95% (+8.38)
Feb 09, 2024
2024 (Q3)
-0.36 / -1.86
-3.84451.48% (+1.98)
Nov 09, 2023
2024 (Q2)
-1.12 / -3.06
-3.3468.51% (+0.28)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CGC Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 07, 2025
$1.09$1.17+7.34%
Aug 08, 2025
$1.05$1.25+19.05%
May 30, 2025
$1.71$1.32-22.81%
Feb 07, 2025
$2.78$2.02-27.34%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Canopy Growth (CGC) report earnings?
Canopy Growth (CGC) is schdueled to report earning on Feb 06, 2026, Before Open (Confirmed).
    What is Canopy Growth (CGC) earnings time?
    Canopy Growth (CGC) earnings time is at Feb 06, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CGC EPS forecast?
          CGC EPS forecast for the fiscal quarter 2026 (Q3) is -0.06.

            Canopy Growth (CGC) Earnings News

            Canopy Growth Stock (TSE:WEED) Plunges after Disappointing Q4 Earnings
            Premium
            Market News
            Canopy Growth Stock (TSE:WEED) Plunges after Disappointing Q4 Earnings
            2y ago
            CGC Craters on Weak Earnings; Lays Off 60% of Workforce
            Premium
            Market News
            CGC Craters on Weak Earnings; Lays Off 60% of Workforce
            3y ago
            Canopy (Non) Growth: Weed Company Disappoints Again in Fiscal Q2
            Premium
            Market News
            Canopy (Non) Growth: Weed Company Disappoints Again in Fiscal Q2
            3y ago
            Canopy Growth Stock Recovers from Earnings Miss; Shares Up 15%
            Premium
            Market News
            Canopy Growth Stock Recovers from Earnings Miss; Shares Up 15%
            3y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis